254 related articles for article (PubMed ID: 34239990)
1. Oligometastatic non-small cell lung cancer: Current management.
Román-Jobacho A; Hernández-Miguel M; García-Anaya MJ; Gómez-Millán J; Medina-Carmona JA; Otero-Romero A
J Clin Transl Res; 2021 Jun; 7(3):311-319. PubMed ID: 34239990
[TBL] [Abstract][Full Text] [Related]
2. Changing equipoise in the landscape of radiation for oligometastatic lung cancer.
Schroeder SR; Leenders M; Iyengar P; de Ruysscher D
Transl Lung Cancer Res; 2019 Sep; 8(Suppl 2):S184-S191. PubMed ID: 31673523
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer.
Wujanto C; Vellayappan B; Siva S; Louie AV; Guckenberger M; Slotman BJ; Onishi H; Nagata Y; Liu M; Lo SS
Front Oncol; 2019; 9():1219. PubMed ID: 31799188
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiation therapy for lung, spine and oligometastatic disease: current evidence and future directions.
Dunne EM; Fraser IM; Liu M
Ann Transl Med; 2018 Jul; 6(14):283. PubMed ID: 30105233
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic Body Radiotherapy - Current Indications.
Burkoň P; Slavik M; Kazda T; Pospíšil P; Prochazka T; Vrzal M; Šlampa P
Klin Onkol; 2019; 32(1):10-24. PubMed ID: 30894002
[TBL] [Abstract][Full Text] [Related]
9. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial.
Trovo M; Furlan C; Polesel J; Fiorica F; Arcangeli S; Giaj-Levra N; Alongi F; Del Conte A; Militello L; Muraro E; Martorelli D; Spazzapan S; Berretta M
Radiother Oncol; 2018 Jan; 126(1):177-180. PubMed ID: 28943046
[TBL] [Abstract][Full Text] [Related]
10. Local ablative radiotherapy for oligometastatic non-small cell lung cancer.
Suh YG; Cho J
Radiat Oncol J; 2019 Sep; 37(3):149-155. PubMed ID: 31591862
[TBL] [Abstract][Full Text] [Related]
11. Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update.
Chen YH; Ho UC; Kuo LT
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267658
[TBL] [Abstract][Full Text] [Related]
12. Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy.
Dohopolski M; Iyengar P
Ann Palliat Med; 2021 May; 10(5):5944-5953. PubMed ID: 33691460
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
[TBL] [Abstract][Full Text] [Related]
14. The evolving role of radiotherapy in treatment of oligometastatic NSCLC.
Bergsma DP; Salama JK; Singh DP; Chmura SJ; Milano MT
Expert Rev Anticancer Ther; 2015; 15(12):1459-71. PubMed ID: 26536370
[TBL] [Abstract][Full Text] [Related]
15. Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions.
Couñago F; Luna J; Guerrero LL; Vaquero B; Guillén-Sacoto MC; González-Merino T; Taboada B; Díaz V; Rubio-Viqueira B; Díaz-Gavela AA; Marcos FJ; Del Cerro E
World J Clin Oncol; 2019 Oct; 10(10):318-339. PubMed ID: 31799148
[TBL] [Abstract][Full Text] [Related]
16. A patient with metastatic non-small cell lung cancer who received pembrolizumab monotherapy after stereotactic body radiotherapy had progression-free survival of nearly 5 years: a case report.
Ni J; Yang L; Zhu H; Chu M; Zhang C; Zhao W; Yang M; Xu X; Zheng E; Jiang X; Li R; Zhao G
Ann Palliat Med; 2021 Apr; 10(4):4999-5009. PubMed ID: 33966436
[TBL] [Abstract][Full Text] [Related]
17. The current state of oligometastatic and oligoprogressive non-small cell lung cancer.
Tumati V; Iyengar P
J Thorac Dis; 2018 Aug; 10(Suppl 21):S2537-S2544. PubMed ID: 30206497
[TBL] [Abstract][Full Text] [Related]
18. Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Juan O; Popat S
Clin Lung Cancer; 2017 Nov; 18(6):595-606. PubMed ID: 28377206
[TBL] [Abstract][Full Text] [Related]
19. Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review.
Kent CL; McDuff SGR; Salama JK
Ann Palliat Med; 2021 May; 10(5):5954-5968. PubMed ID: 32921069
[TBL] [Abstract][Full Text] [Related]
20. The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review.
Berzenji L; Debaenst S; Hendriks JMH; Yogeswaran SK; Lauwers P; Van Schil PE
Transl Lung Cancer Res; 2021 Jul; 10(7):3409-3419. PubMed ID: 34430376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
